Tricyclo Ring System Having The Hetero Ring As One Of The Cyclos Patents (Class 514/454)
-
Publication number: 20120220650Abstract: A functional microbially fermented tea extract containing a novel polyphenol derivative and a method for producing the same are provided. A functional microbially fermented tea extract containing various extracts and a novel polyphenol derivative is produced by subjecting, to an extraction treatment, a microbially fermented tea leaf obtained by culturing one species selected from Aspergillus sp. (PK-1), Aspergillus oryzae (NBRS 4214) sp. (AO-1), Aspergillus awamori (NBRS 4122) sp. (SK-1), and Eurotium sp. (KA-1) with a tea leaf. Furthermore, for example, a functional fermented tea extract enriched with a novel polyphenol derivative is produced.Type: ApplicationFiled: September 17, 2010Publication date: August 30, 2012Applicants: KABUSHIKI KAISHA RIVERSON, NAGASAKI PREFECTURAL UNIVERSITY CORPORATION, SAGA UNIVERSITYInventors: Teruyoshi Yanagita, Kanji Ishimaru, Takashi Tanaka, Kazunori Koba, Hitoshi Miyazaki, Naohito Aoki, Denbei Kawamura
-
Publication number: 20120207809Abstract: Methods and systems are described for a rapid and sustainable change in the pigment melanin content of melanocytes of the iris stroma, thereby to change the color of the eye. Also described are compositions for lightening or darkening the pigmented tissues or treating a pigmented tissue disease.Type: ApplicationFiled: November 30, 2011Publication date: August 16, 2012Inventor: Kambiz Thomas Moazed
-
Publication number: 20120196881Abstract: This disclosure relates generally to methods and pharmaceutical compositions useful in treating pulmonary hypertension. In one embodiment, for example, the disclosure provides a method for treating pulmonary hypertension comprising administering a therapeutically effective dose of a carbonic anhydrase inhibitor to a patient in need of treatment. The disclosure finds utility in the fields of medicine and pharmacology.Type: ApplicationFiled: December 5, 2011Publication date: August 2, 2012Applicant: Vivus, Inc.Inventors: Thomas Najarian, Peter Y. Tam, Leland F. Wilson, Craig Peterson
-
Publication number: 20120190735Abstract: There is described a therapeutic agent capable of directly or indirectly having an effect on the proteins N-methyl-D-aspartate (NMDA), Cyclooxygenase-2 (COX-2), Tumour Necrosis factor alpha (TNF-a), Nuclear factor-kappa B (NFKB), Cyclin-dependent kinases, e.g. CDK2/A and CDK5/p25, Histone acetyltransferase (HAT) and Farnesyltransferase, simultaneously, sequentially or separately. There is especially described dexanabinol, or a derivative thereof, as the therapeutic agent.Type: ApplicationFiled: September 10, 2010Publication date: July 26, 2012Applicant: E-THERAPEUTICS PLCInventors: Malcolm Philip Young, Philip McKeown
-
Patent number: 8227627Abstract: Described herein are ?9-THC prodrugs, methods of making ?9-THC prodrugs, formulations comprising ?9-THC prodrugs and methods of using ?9-THC. One embodiment described herein relates to the transdermal administration of a ?9-THC prodrug for treating and preventing diseases and/or disorders.Type: GrantFiled: December 1, 2008Date of Patent: July 24, 2012Assignee: Alltranz Inc.Inventors: Audra Lynn Stinchcomb, Miroslaw Jerzy Golinski, Dana Carmel Hammell, Jeffery Lynn Howard
-
Publication number: 20120183606Abstract: The invention relates to drug delivery systems comprising a water-soluble polymer matrix and a bioactive agent entrained therein, said water soluble polymer matrix containing at least 50 wt. % of polyoxazoline having a molar mass of at least 5 40,000 g/mol. The drug delivery systems of the present invention offer the advantage that the bioactive agent is readily released when the drug delivery system is contacted with water. The drug delivery system can be in the form of a solid dispersion, a mucoadhesive sheet, a tablet, a powder, a capsule.Type: ApplicationFiled: June 28, 2010Publication date: July 19, 2012Inventors: Johannes Caspar Mathias Elizabeth Bender, Richard Hoogenboom, Patrick Andreas Anton van Vliet
-
Patent number: 8222292Abstract: Oral cannabinoid formulations, including an aqueous-based oral dronabinol solution, that are stable at room or refrigerated temperatures and may possess improved in vivo absorption profiles with faster onset and lower inter-subject variability.Type: GrantFiled: August 31, 2011Date of Patent: July 17, 2012Assignee: Insys Therapeutics, Inc.Inventors: Venkat R. Goskonda, Ashok Chavan, Amit Kokate, Howard Gill
-
Publication number: 20120172751Abstract: The disclosure relates to the discovery that certain cerebrovascular disorders in humans who exhibit seemingly normal intracranial pressure (ICP) and do not exhibit hydrocephalus can be alleviated or prevented by reducing ICP in the human. Disorders of this type are herein designated normotensive, nonhydrocephalus tenso-responsive cerebrovascular disorder (NNTCDs). The disclosure describes methods of relieving head pain and other symptoms of NNTCDs, for example by withdrawing cerebrospinal fluid (CSF) from the subarachnoid space of a human or by administering a pharmaceutical agent that modulates CSF production, uptake, or both. Methods of assessing whether a human is afflicted with one or more NNTCDs are also described. The disclosure describes numerous pharmaceutical compositions suitable for administration to humans afflicted with NNTCDs to alleviate or prevent such disorders. Such compositions can, for example, include both a CSF-reducing agent and a symptomatic (e.g., head pain) relief agent.Type: ApplicationFiled: September 6, 2011Publication date: July 5, 2012Inventor: Bruce H. LEVIN
-
Publication number: 20120165402Abstract: This invention relates to the use of one or more cannabinoids in the treatment of epilepsy and more particularly to the use of one or a combination of cannabinoids in the treatment of generalized or partial seizure. In one embodiment it relates to the use of the cannabinoid THCV, as a pure or isolated compound, or as a plant extract in which significant amounts of any THC naturally present has been selectively removed. In another embodiment the phytocannabinoid is CBD.Type: ApplicationFiled: June 29, 2010Publication date: June 28, 2012Applicants: Otsuka Pharmaceutical Co., Limited, GW Pharma LimitedInventors: Ben Whalley, Gary Stephens, Claire Willaims, Geoffrey Guy, Stephen Wright, Tetsuro Kikuchi
-
Publication number: 20120148689Abstract: The present invention is related to the composition and methods of manufacture of orally-dissolvable, edible films as a vehicle for the non-invasive administration of active drugs through the mucosal tissues of the oral cavity. The films include a water soluble film-forming polymer such as pullulan. Methods for producing the films are also disclosed.Type: ApplicationFiled: February 17, 2012Publication date: June 14, 2012Inventor: Todd Maibach
-
Publication number: 20120142650Abstract: Methods of treating lung diseases comprising administering inducers of NAD(P)H:quinone oxidoreductase 1 (NQO1) are disclosed. Inducers of NQO1 include naphthoquinones such as ?-lapachone. Methods of predicting whether a subject with a lung disease will respond to treatment with a naphthoquinone are also described herein.Type: ApplicationFiled: December 7, 2011Publication date: June 7, 2012Inventors: John Hollingsworth, William Michael Foster, Erin Potts Kant, Zhuowei Li
-
Publication number: 20120122966Abstract: An organic dye from the group of crystal violet, gentian violet, malachite green oxalate and rhodamine 6G used as an analgesic agent in the form of a solution with the agent dosage ranging from 0.000001 mg to 10 g per intake. It is preferable to take the agent at least two times a day. In particular cases of use the agent is administered by mouth in the form of an aqueous solution before or after meals, or it is administered per rectum in the form of an aqueous solution, or a 1% solution of the agent is administered intravenously, or the agent is used in the form of a 1-5% ointment, or the agent is administered per rectum in the form of suppositories, and when arresting cancer pain the agent is injected into the tumor (under the tumor) or into a metastasis.Type: ApplicationFiled: April 14, 2009Publication date: May 17, 2012Inventor: Mikhail Vladimirovich Kutushov
-
Publication number: 20120122917Abstract: This invention discloses cannabinoid derivatives and pharmaceutical uses thereof.Type: ApplicationFiled: January 23, 2012Publication date: May 17, 2012Inventor: Craig Rick Travis
-
Patent number: 8178577Abstract: The present invention relates to certain tricyclic derivatives which are capable of inhibiting histone deacetylases. The compounds of this invention are therefore useful in treating diseases associated with abnormal histone deacetylase activities. Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical compositions comprising these compounds, and methods of preparing these compounds are also disclosed.Type: GrantFiled: May 8, 2009Date of Patent: May 15, 2012Assignee: Shenzhen Chipscreen Biosciences Ltd.Inventors: Xian-Ping Lu, Zhi-Bin Li, Zhi-Qiang Ning
-
Publication number: 20120114714Abstract: Disclosed is a pharmaceutical composition for the treatment and/or prevention of erectile dysfunction, comprising (a) a therapeutically effective amount of a compound represented by Formula 1 or 2, and (b) a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof.Type: ApplicationFiled: January 13, 2012Publication date: May 10, 2012Inventors: Taehwan KWAK, Myung-Gyu Park, Sang-Ku You
-
Patent number: 8173698Abstract: The present invention provides fluorogenic probes and corresponding fluorescent compounds, methods of using the probes, compounds and kits that include the probes.Type: GrantFiled: February 29, 2008Date of Patent: May 8, 2012Assignee: Life Technologies CorporationInventors: Iain Johnson, Jixiang Liu, Brian Patch, Wai-Yee Leung
-
Publication number: 20120107300Abstract: Cannabinoid compositions and methods of administering said cannabinoid compositions are disclosed. The cannabinoid compositions disclosed herein include compounds which have been strategically selected to eliminate, or least mitigate, one of the negative side effects associated with consuming cannabinoids. A daytime formula includes compounds aimed at nullifying the negative side effects that cannabinoid consumption has on a patient's daily operations and activities. A nighttime formula includes compounds aimed at nullifying the negative side effects that cannabinoid consumption has a patient's sleep.Type: ApplicationFiled: November 1, 2010Publication date: May 3, 2012Inventor: Jeffrey Nathan Schirripa
-
Publication number: 20120095087Abstract: A process for producing a composition with bioactive and/or bioavailable Cannabis-derived cannabinoids known to be effective for CB1 and/or CB2 modulation, and a plurality of indications for patients in need. Using a heat cycle process to combine cannabinoids, including but not limited to THC and CBD with flax seed oil and at least one of the triglycerides therein, an extract is formulated which enables substantially profiled and Cannabinoid ratio-balanced aliquots (“miquots”) to be offered for consideration to patients, including non-psychoactive topically and orally delivered products and systems.Type: ApplicationFiled: April 20, 2011Publication date: April 19, 2012Inventor: Keith Hyatt
-
Publication number: 20120095088Abstract: The invention is a product and a process wherein cannabinoids such as Medicinal ?9-THC and/or other substances associated with medicinal cannabis, including yet not necessarily limited to cannbidiols, cannabigerol are contained or processed into foodstuffs or medicinal compounds in controlled ways and with specific characteristics. First a medicinal substance with a known about of medicinal cannabis is mixed into a foodstuff such that the medicinal cannabis is distributed uniformly in the foodstuff. Foodstuffs consistent with this invention include baked goods, hard candies, ice cream, bases, ice cream, and yogurt. The product is characterized by a controlled amount of cannabinoids per unit volume of the foodstuff. Another provision of the invention is providing controlled amounts or ratios of ?9-THC as compared to CBD in a foodstuff.Type: ApplicationFiled: August 19, 2011Publication date: April 19, 2012Inventor: Andrew David Hospodor
-
Publication number: 20120095089Abstract: Disclosed is a method for preventing or treating an undesirable condition in a subject carrying cells homozygous null for the neurofibromatosis type 1 gene or subjects that are haploinsufficient for the neurofibromatosis type 1 gene, the method comprising administering to a subject in need thereof an effective amount of a schweinfurthin or schweinfurthin analog or derivative, or a pharmaceutically acceptable salt, prodrug, hydrate, or solvate thereof. Also disclosed is a new schweinfurthin compound of the formula.Type: ApplicationFiled: April 30, 2010Publication date: April 19, 2012Applicants: UNIVERSITY OF IOWA RESEARCH FOUNDATION, THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Karlyne Reilly, Thomas Turbyville, John A. Beutler, David Wiemer
-
Patent number: 8148423Abstract: Provided herein are fluorophore compounds including rhodol and rhodamine compounds which can be used as fluorescent labels and/or fluorogenic probes and methods of making same. Provided also herein are methods that can be used to track, measure, detect, or screen biological species such as protein, DNA, enzyme, antibody, organelle, cell, tissue, drug, hormone, nucleotide, nucleic acid, polysaccharide or lipid in living organisms. Specifically, the methods include the steps of contacting any of the fluorophore compounds, rhodol compounds and rhodamine compounds disclosed herein with the biological species to form one or more fluorescent compounds, and measuring fluorescence properties of the fluorescent compounds. Provided also herein are high-throughput screening fluorescent methods for detecting or screening biological species.Type: GrantFiled: April 3, 2009Date of Patent: April 3, 2012Assignees: Versitech Limited, Morningside Ventures LimitedInventors: Dan Yang, Tao Peng
-
Publication number: 20120076848Abstract: Methods and systems are described for a rapid and sustainable change in the pigment melanin content of melanocytes of the iris stroma, thereby to change the color of the eye. Also described are nanoparticle compositions for lightening the pigmented tissues or treating a pigmented tissue related disease.Type: ApplicationFiled: July 21, 2010Publication date: March 29, 2012Inventor: Kambiz Thomas Moazed
-
Patent number: 8133887Abstract: The invention relates to compounds of the formula (I), in which R1, R2, R3, R4, Y and A have the meanings indicated, and to processes for the preparation thereof and to the use thereof for the preparation of medicaments.Type: GrantFiled: November 29, 2006Date of Patent: March 13, 2012Assignee: Merck Patent GmbHInventors: Andreas Taugerbeck, Detlef Pauluth, Beate Kretschmer, Hanns Wurziger, Axel Jansen, David Maillard
-
Publication number: 20120058170Abstract: The invention generally relates to carbon nanotube based drug delivery methods, devices, and compositions. More particularly, the invention relates to controlled drug delivery using anchored carbon nanotube arrays.Type: ApplicationFiled: September 1, 2011Publication date: March 8, 2012Applicant: Califomia Institute of TechnologyInventors: Morteza Gharib, Adrianus Indrat Aria, Masoud Beizai
-
Publication number: 20120052119Abstract: Embodiments of the present invention are directed to articles of manufacture and methods of making such articles having utility for the delivery of cannabinoids as a therapeutic. One embodiment of the present invention directed to the article of manufacture comprises a lyophilized particle or sphere having a diameter of about 100 to 500 nanometers having a shell and comprising a biodegradeable polymer containing a cannabinoid. A featured cannabinoid is delta-9-tetrahydrocannabinol (delta-9-THC).Type: ApplicationFiled: August 23, 2011Publication date: March 1, 2012Inventors: Trevor Percival CASTOR, Geoffrey Purdum
-
Patent number: 8124640Abstract: Pharmaceutical composition comprising 5 to 20% of an idazoxan salt or of idazoxan hydrate, 10 to 40% of microcrystalline cellulose, 1 to 5% of lubricant, 0.1 to 0.5% of colloidal silica and from 29.5% to 84.8% of lactose, with respect to the total mass.Type: GrantFiled: January 17, 2008Date of Patent: February 28, 2012Assignee: Pierre Fabre MedicamentInventors: Joël Bougaret, Jean-Louis Avan, Roland Segonds
-
Publication number: 20120046352Abstract: The invention is a process for the controlled decarboxylation of cannabis wherein Medicinal Delta-9 tetrahydrocannabinol (?9-THC) and other cannabinoid medicinal substances are decarboxylated through a chemical reaction facilitated by a cofactor. The amount of medicinal cannabis decarboxylated will be directly proportional to the amount of cofactor used. Use a small amount of the cofactor and only some of the medicinal cannabis contained in raw cannabis will be converted from an acidic form into a non-acidic form. Use a large amount of the cofactor and most or all of the medicinal cannabis will be decarboxylated. The reaction is proportional to the molar mass of cofactor.Type: ApplicationFiled: August 19, 2011Publication date: February 23, 2012Inventor: Andrew David Hospodor
-
Publication number: 20120046351Abstract: The invention is a product and a process wherein cannabinoids such as Medicinal ?9-THC and/or other substances associated with medicinal cannabis, including yet not necessarily limited to cannbidiols, cannabigerol are added to a foodstuff where the medicinal cannabis is not evenly distributed throughout the foodstuff where the food stuff contains a known weight of medicinal cannabis. Another provision of the invention is providing controlled amounts or ratios of ?9-THC as compared to CBD in or on a foodstuff.Type: ApplicationFiled: August 19, 2011Publication date: February 23, 2012Inventor: Andrew David Hospodor
-
Publication number: 20120043242Abstract: The invention is a product and a process wherein Medicinal Delta-9 tetrahydrocannabinol (?9-THC) and potentially other cannabinoids (medicinal cannabis substances) associated with decarboxylated cannabis, including yet not necessarily limited to cannbidiols, and cannabigerol are rendered into a fatty foodstuff and then molded into a mold that also acts as a package. The best mode of the invention is a blister pack containing a plurality of voids or receptacles of desired sizes. A product that is characterized by a controlled amount of medicinal cannabis per unit volume of a fatty foodstuff base material is inserted into the mold, then cooled, and finally sealed. Each void or receptacle contains a known amount of medicinal cannabis that are independently dispensable.Type: ApplicationFiled: April 4, 2011Publication date: February 23, 2012Inventor: Andrew David Hospodor
-
Patent number: 8114904Abstract: Provided herein are compounds or fluorogenic probes which can be used as reagents for measuring, detecting and/or screening ROS or RNS such as peroxynitrite or hypochlorite. Provided also herein are methods that can be used to measure, directly or indirectly, the amount of peroxynitrite or hypochlorite in chemical samples and biological samples such as cells and tissues in living organisms. Specifically, the methods include the steps of contacting the fluorogenic probes disclosed herein with the samples to form one or more fluorescent compounds, and measuring fluorescence properties of the fluorescent compounds. Provided also herein are high-throughput screening fluorescent methods for detecting or screening peroxynitrite or compounds that can increase or decrease the level of peroxynitrite or hypochlorite in chemical and biological samples.Type: GrantFiled: April 3, 2009Date of Patent: February 14, 2012Assignee: Versitech Limited & Morningside Ventures LimitedInventors: Dan Yang, Tao Peng
-
Publication number: 20120034293Abstract: The present invention overcomes the problems associated with existing drug delivery systems by delivering cannabinoids transdermally. Preferably, the cannabinoids are delivered via an occlusive body (i.e., a patch) to alleviate harmful side effects and avoid gastrointestinal (first-pass) metabolism of the drug by the patient.Type: ApplicationFiled: October 12, 2011Publication date: February 9, 2012Applicant: AllTranz Inc.Inventors: Audra L. Stinchcomb, Buchi N. Nalluri
-
Publication number: 20120027815Abstract: The invention relates to the use of plasma membrane calcium ATPase (PMCA) inhibitors for inhibiting sperm mobility to achieve a contraceptive effect. The invention further relates to contraceptive agents comprising one or more PMCA inhibitors.Type: ApplicationFiled: August 2, 2011Publication date: February 2, 2012Inventor: Ludwig Neyses
-
Publication number: 20120022103Abstract: The present application is directed to compounds that are TRPV1 antagonists and have formula (I) wherein variables Ar1, L1, R1, R2, R3, R4, R5, Y1, Y2, and Y3, are as defined in the description, which are useful for treating disorders caused by or exacerbated by vanilloid receptor activity.Type: ApplicationFiled: September 29, 2011Publication date: January 26, 2012Applicant: ABBOTT LABORATORIESInventors: Erol K. Bayburt, Jerome F. Daanen, Arthur R. Gomtsyan, Steven P. Latshaw, Chih-hung Lee, Robert G. Schmidt, JR.
-
Publication number: 20120022063Abstract: The invention relates to (among other things) oligomer-cannabinoid conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered un-conjugated cannabinoid compounds.Type: ApplicationFiled: February 6, 2009Publication date: January 26, 2012Applicant: Nektar TherapeuticsInventors: Jennifer Riggs-Sauthier, C. Simone Jude-Fishburn, Guy Lalonde
-
Patent number: 8101655Abstract: A fluorescent dye comprising a xanthene-derived fluorophore having the formula (I) wherein R1, R2, R3, R4, R5 and R6 are independently selected from H, alkyl, alkoxy, alcohol, ether, alkenyl, alkenoxy, aryl, aralkyl and amido, except that R1, R4 and/or R5 is not H when bonded to Y, Y1 or Y2, respectively; X is either O? or S?; and at least one of Y, Y1, Y2, Y3, Y4 and Y5 is a group for covalently bonding the dye, optionally through, the use of a coupling agent, to a target molecule, and is otherwise H. The dye may be covalently attached to a target molecule to form a complex, and the dye and/or complex finds use in cell analysis techniques, particularly pH measurement and analysis of kinetics of migration.Type: GrantFiled: January 27, 2010Date of Patent: January 24, 2012Inventors: Gerald Arthur Smith, Darren William Watson, Howard Paul Voorheis
-
Publication number: 20120015331Abstract: The present invention provides a polymeric scaffold containing an antibacterial photoactive drug and optionally comprising seeded cells such as stem cells. The invention also includes methods of using the scaffold for tissue regeneration, prevention or reduction of infection whilst tissue regeneration occurs, methods for improving graft or implant survival, promoting scaffold integration and tissue repair and wound healing.Type: ApplicationFiled: March 23, 2010Publication date: January 19, 2012Inventors: Simon Wood, Xuebin Yang, Marcel de Matas, Peter Iddon, Michael Raxworthy
-
Publication number: 20120010279Abstract: A composition comprising a tetrahydrocannabinol compound, a solvent and an acid, wherein the tetrahydrocannabinol compound may be ?8 tetrahydrocannabinol, (?)-?9-trans-tetrahydrocannabinol or a side chain alkyl derivative of either compound, the solvent may be an oil or C1-C4 alcohol (e.g. sesame oil or ethanol), and the acid may be an organic acid or a mineral acid.Type: ApplicationFiled: September 20, 2011Publication date: January 12, 2012Applicant: Johnson Mathey Public Limited CompanyInventors: Ronald Rossi, Lee Jonathan Silverberg, Robert Hogan, Ramesh M. Shah
-
Patent number: 8093288Abstract: Genipin derivatives and pharmaceutical compositions thereof that inhibit the activity of uncoupling protein-2 (UCP2) and are useful in treating deficient first-phase insulin secretion, non-insulin dependent diabetes mellitus, and ischemia in a mammal are disclosed.Type: GrantFiled: November 19, 2009Date of Patent: January 10, 2012Assignees: Beth Israel Deaconess Medical Center, Trustees of Boston UniversityInventors: Chen-Yu Zhang, Bradford B. Lowell, John A Porco, Jr., Ruichao Shen, Cheng T. Lin, Stefan Krauss
-
Publication number: 20120003301Abstract: Provided are methods of applying a tissue marking to a tissue and rendering said tissue marking colorless when desired, comprising implanting into the tissue an amount of the tissue marking in sufficient quantity to form a detectable marking, said tissue marking comprising at least one colored compound comprising a thermally activatable fragmentation group and at least one infrared absorbing compound, wherein the at least one colored compound is capable of being rendered colorless by unimolecular fragmentation of the thermally activatable fragmentation group when the tissue marking is non-imagewise exposed by a source of infrared radiation and applying sufficient infrared radiation to a sufficient amount of the tissue marking to render the tissue marking colorless when desired.Type: ApplicationFiled: September 15, 2011Publication date: January 5, 2012Applicant: PERFORMANCE INDICATOR LLCInventors: Satish Agrawal, Roger Boggs
-
Publication number: 20120004251Abstract: This invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) and combinations of the phytocannabinoid CBDV with tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in the treatment of epilepsy. The invention further relates to the use of the phytocannabinoid CBDV in combination with standard anti-epileptic drugs (SAEDs). Preferably the SAED is one of ethosuximide, valproate or phenobarbital.Type: ApplicationFiled: March 30, 2011Publication date: January 5, 2012Applicants: Otsuka Pharmaceutical Co., Limited, GW Pharma LimitedInventors: Ben Whalley, Claire Williams, Gary Stephens, Takashi Futamura
-
Publication number: 20110319481Abstract: Methods and intermediates for preparing enantiomerically enriched Schweinfurthin analogs which are useful for the treatment of cancer, as well as novel Schweinfurthin analogs having anti-cancer activity, compositions comprising such analogs and therapeutic methods comprising administering such analogs.Type: ApplicationFiled: January 26, 2011Publication date: December 29, 2011Applicants: Government of the United States of America, National Institute of Health, University of Iowa Research FoundationInventors: David F. Wiemer, Jeffrey D. Neighbors, John A. Beutler
-
Publication number: 20110319352Abstract: The invention relates in part to the discovery that certain CRAMs, such as schweinfurthin A, target OSBPs (a family of oxysterol binding proteins). Because OSBPs have been shown to be integral to atherosclerosis and Alzheimer's disease (AD), one aspect of the invention relates to the use of CRAMs, or a pharmaceutically acceptable salt, biologically active metabolite, solvate, hydrate, prodrug, enantiomer or stereoisomer thereof, in the treatment and/or prevention of atherosclerosis, Alzheimer's disease and related disorders. Another aspect of the invention relates to novel derivatives of CRAMs, or a pharmaceutically acceptable salt, biologically active metabolite, solvate, hydrate, prodrug, enantiomer or stereoisomer thereof, for the treatment and/or prevention of atherosclerosis, Alzheimer's disease and related disorders. Another aspect of the invention relates to the use of an immobilized CRAMs, such as OSW-I, to aid in screening of compounds to identify additional OSBP binders.Type: ApplicationFiled: December 11, 2009Publication date: December 29, 2011Applicant: President and Fellows of Harvard CollegeInventors: Matthew D. Shair, Anthony Burgett, D. Ryan Anderson
-
Patent number: 8084491Abstract: The subject invention provides methods of promoting wound healing comprising the administration of a therapeutically effective amount of a composition comprising topiramate. Compositions may administered to a wound site via a salve, ointment, or as a component of a bandage or bioadhesive applied to the site of injury.Type: GrantFiled: July 31, 2007Date of Patent: December 27, 2011Assignee: Novodermix International LimitedInventors: Nathan Andrew Shapira, Mary Catherine Lessig, Daniel John Driscoll
-
Publication number: 20110312911Abstract: Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.Type: ApplicationFiled: February 3, 2010Publication date: December 22, 2011Inventors: Roman Kats-Kagan, Christian P. Stevenson, Xibin Liao, Qinghong Fu, Emma R. Parmee, Songnian Lin
-
Publication number: 20110306660Abstract: Oral cannabinoid formulations, including an aqueous-based oral dronabinol solution, that are stable at room or refrigerated temperatures and may possess improved in vivo absorption profiles with faster onset and lower inter-subject variability.Type: ApplicationFiled: August 31, 2011Publication date: December 15, 2011Inventors: Venkat R. Goskonda, Ashok Chavan, Amit Kokate, Howard Gill
-
Publication number: 20110300074Abstract: This invention pertains generally to processes, uses, methods and materials utilising particular xanthylium compounds, including compounds of formula (I) and (II), as further defined herein. These compounds are useful as drugs, for example, in the treatment of tauopathies, such as Alzheimer's disease.Type: ApplicationFiled: December 10, 2009Publication date: December 8, 2011Inventors: Scott Clunas, John Mervyn David Storey, Janet Elizabeth Rickard, David Horsley, Charles Robert Harrington, Claude Michel Wischik
-
PREVENTION OF BACTERIAL GROWTH AND BIOFILM FORMATION BY LIGANDS THAT ACT ON CANNABINOIDERGIC SYSTEMS
Publication number: 20110301078Abstract: A group of antimicrobial compounds shows effectiveness for preventing bacterial growth and bio film formation. In particular, the compounds are effective for preventing the growth of gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (“MRSA”) bacteria. The compounds include naturally-occurring compounds such as linoleyl ethanolamide, noladin ether, and anandamide, and man-made compounds such as CP55,640 [(?)-cis-3-[2-Hydroxy-4-(l,l-dimethylheptyl)phenyl]-tran s-4-(3-hydroxypropyl)cyclohexanol] and O-2050 [(6aR,10aR)-3-(l-Methanesulfonylamino-4-hexyn-6-yl)-6a, 7,10,1 Oa-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran]. Because these antibacterial compounds have unique modes of action and/or unique chemical scaffolds compared to traditional antibiotics, they are extremely useful against bacteria having resistances to antibiotics.Type: ApplicationFiled: June 25, 2009Publication date: December 8, 2011Inventors: John A. Schetz, Sally A. Hoger -
Patent number: 8071641Abstract: Use of a cannabidiol for the manufacture of a medicament identified for the treatment or prevention of diabetes and/or insulitis.Type: GrantFiled: February 16, 2005Date of Patent: December 6, 2011Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem, Hadsit Hadasit Medical Research Services and Development Ltd.Inventors: Lola Weiss, Michael Zeira, Raphael Mechoulam, Shimon Slavin, Ruth Gallily
-
Publication number: 20110287099Abstract: Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.Type: ApplicationFiled: December 17, 2010Publication date: November 24, 2011Inventors: Likan Liang, Hua Wang, Padmanabh P. Bhatt, Michael L. Vieira
-
Publication number: 20110286926Abstract: This invention concerns an in situ biodegradable hydrogel drug delivery system in which the components are assembled in a manner that provides a mechanism for the timed cleavage of a particular amide bond in a covalently linked active agent or of the hydrogel structure.Type: ApplicationFiled: November 20, 2009Publication date: November 24, 2011Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Patrick J. Sinko, Manjeet Deshmukh, Yashveer Singh, Simi Gunaseelan